Imetabolic Biopharma Corporation

Phoenix, AZ

UEI
YB81A2HDHT65
CAGE
81TS4
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Asian-Pacific American Owned
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
275 N Gateway Blvd #104, Phoenix, AZ 85034, USA
Website
imbiopharma.com
Founded
2017
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Imetabolic Biopharma Corporation's 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Therapeutic approach to clear sdldl from circulation - project abstract cardiovascular disease (CVD) is a significant… Grant · R43HL174270 National Heart Lung and Blood Institute $299,504
Computational development of novel dyslipidemia therapeutic candidates to disrupt apoc-III conformation - project… Grant · R43HL170808 National Heart Lung and Blood Institute $283,123

Quick answers

What is Imetabolic Biopharma Corporation's UEI?

Imetabolic Biopharma Corporation's Unique Entity ID (UEI) in SAM.gov is YB81A2HDHT65.

What is Imetabolic Biopharma Corporation's CAGE code?

Imetabolic Biopharma Corporation's CAGE code is 81TS4.

Where is Imetabolic Biopharma Corporation located?

Imetabolic Biopharma Corporation's physical address in SAM.gov is 275 N Gateway Blvd #104, Phoenix, AZ 85034, USA.

Is Imetabolic Biopharma Corporation registered in SAM.gov?

Yes. Imetabolic Biopharma Corporation's SAM.gov registration is active through March 23, 2027.

What is Imetabolic Biopharma Corporation's most recent federal award?

Imetabolic Biopharma Corporation's most recent federal grant award is Therapeutic approach to clear sdldl from circulation - project abstract cardiovascular disease (CVD) is a significant… (R43HL174270), from National Heart Lung and Blood Institute, on September 15, 2024.

On GovTribe

See Imetabolic Biopharma Corporation's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login